ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

SCLP Scancell Holdings Plc

10.10
0.00 (0.00%)
24 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Scancell Holdings Plc LSE:SCLP London Ordinary Share GB00B63D3314 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 10.10 9.70 10.50 10.10 10.10 10.10 631,989 08:00:28
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 5.27M -11.94M -0.0129 -7.83 93.71M
Scancell Holdings Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker SCLP. The last closing price for Scancell was 10.10p. Over the last year, Scancell shares have traded in a share price range of 7.65p to 18.125p.

Scancell currently has 927,819,977 shares in issue. The market capitalisation of Scancell is £93.71 million. Scancell has a price to earnings ratio (PE ratio) of -7.83.

Scancell Share Discussion Threads

Showing 67001 to 67025 of 67025 messages
Chat Pages: 2681  2680  2679  2678  2677  2676  2675  2674  2673  2672  2671  2670  Older
DateSubjectAuthorDiscuss
25/5/2024
18:45
Thanks Moljen not been the best season for any of us and fine margins and TBH was very unexpected but a bit of glory.
Let us hope we get a right result here as this is definitely my worst performing holding at the moment.
Yes good luck to Loggie.
Enjoy rest of w/ end.
Happy to add here but awaiting positive news which I do expect but am wanting to see what is released and happy enough with current exposure here as the extra would purely be for a trade.
Always feel more comfortable taking a risk if overall you are doing OK

ivyspivey
25/5/2024
17:48
Ivy congrats for today even though it's put us out. Loggie, all the best for tomorrow.
moljen
25/5/2024
15:45
Similar to prior reports regarding ipilimumab3, 4 or nivolumab5 monotherapy, conventional objective response rates may not fully capture the spectrum of clinical activity and potential benefit in patients treated with the concurrent nivolumab/ipilimumab regimen in that a number of patients experienced either long-term SD or unconventional “immune-related” patterns of response. Indeed, even among the 7 patients in the concurrent regimen with SD ≥24 weeks or irSD ≥24 weeks as best response, 6 demonstrated meaningful tumor regression of at least 19%, and the seventh patient has declining tumor burden after prolonged stable disease. Prior experience with checkpoint blockade monotherapy supports the observation that some patients may survive for extended periods of time with SD as the best objective response, lending credence to the hypothesis that re-establishment of the equilibrium phase of immune surveillance is a desirable outcome.1
inanaco
25/5/2024
14:31
which also means the patients get benefit very quickly ...

statistics ...

who would have thought

Thanks Ruck for giving me the incentive !!!

learned loads (self taught)

inanaco
25/5/2024
14:27
so its my conclusion that

The response curve of SCIB1 is far faster than Doublet on its own ..... making an unbiased assessment using the control arm in the trial very difficult to compare at 1st and second scan

unless proved otherwise ...

IMHO

inanaco
25/5/2024
14:21
if you strip out our 24 and 37 week patients because you don't have the 13 week data

which is 6

13 - 6 = 7

so ours is 5 0f 7 or 71%

v 31%

inanaco
25/5/2024
14:11
Although not formally compared in this study, the concurrent nivolumab/ipilimumab regimen achieved objective response rates that exceed the prior reported experience with either nivolumab or ipilimumab alone3, 5.

Most importantly, rapid and deep responses were achieved in a substantial portion of treated patients, with the majority of responding patients having achieved ≥80% tumor regression at the time of the initial tumor assessment, including some with extensive and bulky tumor burden.

""""Particularly striking was the observation that 31% of response-evaluable patients treated across the concurrent-regimen cohorts demonstrated ≥80% tumor regression by week 12."""

v

Treatment Arm

The top-line data from the first stage of the Phase II SCOPE study of SCIB1 in combination with checkpoint inhibitors (CPIs) in advanced melanoma are highly impressive, with an objective response rate (ORR) of 82% (with the target nine responses achieved in only 11 patients). The tumour reduction at 13 weeks is 31-94%, with four patients reaching week 25 achieving a tumour reduction of 69-94%, and two patients reaching the 37-week evaluation achieving 87-94% tumour reduction.

""The tumour reduction at 13 weeks is 31-94%""

inanaco
25/5/2024
14:02
finally found some data from A phase 1 trial ...

Bermuda can now explain why he is correct ... !!





For patients in the sequenced-regimen cohorts, 6 of 30 patients achieved OR (20%; 95% CI: 8-39) including 1 CR. Four (13%) patients achieved ≥80% tumor reduction at 8 weeks (Table 3B and Figures 1C and S2D). Additional patients had immune-related (n=3) or unconfirmed (n=3) responses. When objective, immune–related or unconfirmed responses or SD ≥24 weeks are considered, evidence of clinical activity for the sequenced regimen was observed in 43% (95% CI: 26-63). The waterfall plot reveals that patients who did not respond to prior ipilimumab can respond to subsequent nivolumab (Figure 1D).

inanaco
25/5/2024
13:01
Ruck ever heard the term "wing it"

that is the difference between Evidence based posts 😎 mine

and Posts that are just not backed up .... 🤔

so your attempt to be a "wing man" .. is appropriate 😎

inanaco
25/5/2024
11:34
Might have a towel Sale this week ..... 😄
inanaco
25/5/2024
11:32
""You should know though that although I reduced my holding, I am still invested and want Scancell to succeed every bit as much as you."" Bermuda
inanaco
25/5/2024
11:30
LOL ...

so did you reduce your holdings when Bermuda did Ruck...

If not you clearly have not followed Bermuda

MT has bought more ! so he didn't listen

will you sell down before the next trial as its "so different" ?

inanaco
25/5/2024
11:19
Some great posts from Bermuda.It's good to get the facts straight.Thanks for sharing.
ruckrover
25/5/2024
09:45
Reality

NOT WITHOUT MERIT


Bermudashorts

Posts: 12,656

Price: 10.10

No Opinion

RE: ASCO24 May 2024 11:59
Good grief - on one board I'm slated for being risk adverse and negative and here I'm pumping SCLP. The reality of course is like most here, I simply post as I see it at any given point in time.

Burble - thanks for the kind words, much appreciated and ditto.

inanaco
25/5/2024
09:43
this man is priming you for what he believes

""""Finally you are quite right, I don't buy into your 'no risk' fairytale and it's somewhat ironic that in order to highlight this you quote the results of the original SCIB1 study. A trial that took place over a decade ago, when there were only about 200m shares in issue and the results were so good that they were going to lead to a trade sale for many multiples of the market cap. Here we are nearly 14 years later and nearly 1 billion shares in issue and the share price under 10p. No risk indeed."""

""""""We've seen endless debate on whether Scancell gets to a multi billion dollar valuation or is the next BioNTech, but I honestly don't think that's the investment case here. It certainly isn't for me.""""

Bermudashorts - 27 Apr 2024 - 20:24:10 - 8129 of 9056 Scancell - Pot of Gold or POS? - SCLP
As usual you are fixating on detail to distract. For reasons that I've fully explained:-

1) You can't predict the probability of success for the forthcoming phase II/III based on the probability of success of a completely different trial.

2) Your statement that the probability of success of future trials will always be higher than the objective response rate from the current trial is simply not true.

You say that all you're trying to do is 'give investors some sort of head light going forward' You are suggesting probabilites of success of 90% in a future phase II/III trial - that's not giving a heads up, it's raising expectations to a completely unreasonable level. I don't care how popular or unpopular these posts are but if anyone is managing to follow any of this debate and believes that Scancell's next trial has a 90% probability of success - it doesn't. Even if the current trial reaches that 70% or even 85% threshold - it still doesn't.

inanaco
25/5/2024
09:13
the importance of that post is this

How do you compare two arms with different response curves ?

Scancell is starting a trial in 2025 if the data is good, but its also giving data out in 2025 on that trial

How ........... well that is a question for his Lordship

is 70% a target or the unknown random arm target ? which i have already proven to be a Gold standard at 55% and not accurate for the first 6 months

what is Bermuda scared of ?

without that his

"you cant calculate probability falls over"

"Scancells value is fairy tales"

and "Risk" then applies



Bermudashorts - 29 Apr 2024 - 13:22:55 - 8187 of 9054 Scancell - Pot of Gold or POS? - SCLP
Inanaco,

I'm sorry but Lindy hasn't told me or anyone else as far as I know. The point was in relation to the difference in response rates between the two arms in the planned phase II/III trial. What is that specific figure? If you don't know just admit and correct your post.

inanaco
25/5/2024
08:37
why is this post important ...............

more evidence

Random Arm

When managing disease with apparent treatment failure, we consider the possibility of mixed response or pseudoprogression, which is usually encountered at the first restaging scans; consideration should be given to continuing therapy and obtaining a short interval scan to confirm progression. Notably, 13% of patients treated beyond progression with nivolumab in the CheckMate-025 study experienced a 30% or greater decline in tumor burden. 21

was looking at the Modi1 RCC

but again it shows the level of pseudoprogression can be as high as 13%



v

Treatment Arm

The top-line data from the first stage of the Phase II SCOPE study of SCIB1 in combination with checkpoint inhibitors (CPIs) in advanced melanoma are highly impressive, with an objective response rate (ORR) of 82% (with the target nine responses achieved in only 11 patients). The tumour reduction at 13 weeks is 31-94%, with four patients reaching week 25 achieving a tumour reduction of 69-94%, and two patients reaching the 37-week evaluation achieving 87-94% tumour reduction.

""The tumour reduction at 13 weeks is 31-94%""

inanaco
25/5/2024
06:53
Can i remind you about your Last sentence ....

only you are getting rather boring .. Cancer patients don't just get of a bus and walk in .... they have to go through a lot of screening before given a treatment regime that is quite toxic and HLA restricted with SCIB1 .. but with ISCIB1 open as well this allows those that fail HLA to still get a chance with Scancell.
Scancell can only give guidance when it may be able to release data sadly we are still suffering Covid overhang and strikes by NHS staff, but don't worry VAT on Private education will recover the situation by end of July !!

cant you be happy that they have told you it has a 90% chance of coming good ?

Scinv_temp

Posted in: SCLP

Posts: 1,060

Price: 10.10

No Opinion

RE: Results16 May 2024 14:05
Final, I promise Because I'm allergic to BS. This is what the CEO said in the placing RNS (before the actual placing):

"Commenting on the proposed Capital Raise, Prof Lindy Durrant, Chief Executive Officer, said: “Scancell is producing highly-significant data across its pipeline of cancer vaccines. The recent updates from the SCOPE study are showing previously unseen response rates in melanoma including an objective response rate of over 85 per cent. and a complete responder. The study remains on track with data expected in H1 2024 and based upon the first 13 patients there is a greater than 90% probability that the second phase will also be successful."

H1 2024, so that "Q3" is not very consistent guidance, is it?

In fact it is quite recent.

(OK I'm done)

inanaco
25/5/2024
06:33
more evidence

When managing disease with apparent treatment failure, we consider the possibility of mixed response or pseudoprogression, which is usually encountered at the first restaging scans; consideration should be given to continuing therapy and obtaining a short interval scan to confirm progression. Notably, 13% of patients treated beyond progression with nivolumab in the CheckMate-025 study experienced a 30% or greater decline in tumor burden. 21

was looking at the Modi1 RCC

but again it shows the level of pseudoprogression can be as high as 13%

inanaco
24/5/2024
22:10
Scancell
@scancellpharma
·
49m
On 1 June, we will be presenting data for the Phase 2 SCOPE trial of our cancer vaccine SCIB1 at the
@ASCO
Annual Meeting in Chicago.

marcusl2
24/5/2024
21:35
It's coming
rogerbridge
24/5/2024
20:13
and you Ivy ...
inanaco
24/5/2024
16:49
All have a good long w/ end and another decent week and we go again next week
ivyspivey
24/5/2024
15:15
You're an idiot inane...
Not just barking up the wrong tree ...you're in the wrong forest !

2tyke
24/5/2024
13:47
dont have to see the article maths are clearly presented
inanaco
Chat Pages: 2681  2680  2679  2678  2677  2676  2675  2674  2673  2672  2671  2670  Older

Your Recent History

Delayed Upgrade Clock